Preoperative somatostatin receptor ligands (SRLs) treatment is proven to reduce GH and IGF1 levels (9) and induce tumor shrinkage (10), improving surgical outcomes in acromegaly (11, 12, 13). This evidence concerns the gene GH1 and neoplasm.